| [1] |
Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis, 2011, 11: 324. doi:10.1186/1471-2334-11-324.
|
| [2] |
李虹艾, 李帮涛, 刘鹂, 等. 国内白血病合并结核病临床病例分析. 中国感染与化疗杂志, 2019, 19(3): 243-247. doi:10.16718/j.1009-7708.2019.03.003.
|
| [3] |
中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版). 中华血液学杂志, 2023, 44(9): 705-712. doi:10.3760/cma.j.issn.0253-2727.2023.09.001.
|
| [4] |
Ji L, Yang W, Gao LJ, et al. Treatment of acute myeloid leukemia with active pulmonary tuberculosis with venetoclax-based anti-acute myeloid leukemia regimen combined with an intensive and then individualized anti-tuberculosis regimen: A report of two cases. Oncol Lett, 2024, 28(6): 601. doi:10.3892/ol.2024.14734.
|
| [5] |
Ghafoor T, Khalil S, Farah T, et al. Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from A Developing Country. Cancer Rep (Hoboken), 2020, 3(5): e1259. doi:10.1002/cnr2.1259.
|
| [6] |
王岳, 陈晓娟, 郭晔, 等. CCLG-ALL2008方案治疗儿童急性淋巴细胞白血病死亡病例分析. 中国实验血液学杂志, 2021, 29(3): 720-724. doi:10.19746/j.cnki.issn1009-2137.2021.03.011.
|
| [7] |
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140(12): 1345-1377. doi:10.1182/blood.2022016867.
|
| [8] |
Ostgard LS, Nørgaard JM, Sengeløv H, et al. Impact of chemotherapy delay on short-and long-term survival in younger and older AML patients: a Danish population-based cohort study. Leukemia, 2014, 28(9): 1926-1929. doi:10.1038/leu.2014.157.
pmid: 24813919
|
| [9] |
Jain A, Prakash G, Singh C, et al. Analysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia. Indian J Hematol Blood Transfus, 2017, 34(3): 430-442. doi:10.1007/s12288-017-0875-z.
|
| [10] |
李军, 牛挺. 恶性血液病合并活动性结核病的临床研究进展. 中华血液学杂志, 2013, 34(12): 1076-1079. doi:10.3760/cma.j.issn.0253-2727.2013.12.020.
|
| [11] |
Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov, 2014, 4(3): 362-375. doi:10.1158/2159-8290.CD-13-0609.
pmid: 24346116
|
| [12] |
Griffioen MS, de Leeuw DC, Janssen JJWM, et al. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers (Basel), 2022, 14(14): 3456. doi:10.3390/cancers14143456.
|
| [13] |
Masetti R, Baccelli F, Leardini D, et al. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?. Blood Adv, 2024, 8(13): 3583-3595. doi:10.1182/bloodadvances.2023012041.
|
| [14] |
Ji L, Yang W, Xu XF, et al. A case report of complete remission of acute myeloid leukemia combined with DNMT3A, FLT3-TKD, and IDH2 gene mutations and active pulmonary tuberculosis treated with homeharringtonine+venetoclax+azacytidine. Front Med (Lausanne), 2023, 10:1180757. doi:10.3389/fmed.2023.1180757.
|
| [15] |
DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135(11): 791-803. doi:10.1182/blood.2019003988.
pmid: 31932844
|
| [16] |
Jin H, Zhang Y, Yu S, et al. Venetoclax combined with azacitidine and homoharringtonine in relapsed/refractory AML: A multicenter, Phase 2 trial J Hematol Oncol, 2023, 16(1): 42. doi:10.1186/s13045-023-01437-1.
|
| [17] |
Ramon-Luing LA, Olvera Y, Flores-Gonzalez J, et al. Diverse cell death mechanisms are simultaneously activated in macrophages infected by virulent mycobacterium tuberculosis. Pathogens, 2022, 11(5): 492. doi:10.3390/pathogens11050492.
|
| [18] |
李军, 蒋孟, 羊裔明, 等. 白血病合并活动性结核病44例临床研究——单中心报告. 中华血液学杂志, 2013, 34(7): 572-577. doi:10.3760/cma.j.issn.0253-2727.2013.07.003.
|
| [19] |
World Health Organization.Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
|
| [20] |
中华医学会结核病学分会. 利奈唑胺抗结核治疗专家共识(2022年版). 中华结核和呼吸杂志, 2022, 45(10): 988-995. doi:10.3760/cma.j.cn112147-20220320-00220.
|
| [21] |
Imperial MZ, Nedelman JR, Conradie F, et al. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis, 2022, 74(10): 1736-1747. doi:10.1093/cid/ciab699.
|
| [22] |
首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会,《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版). 中国防痨杂志, 2021, 43(9): 859-866. doi:10.3969/j.issn.1000-6621.2021.09.002.
|
| [23] |
赵卫红, 孙青, 谢瑶, 等. 初诊 ALL 患儿合并潜伏结核感染的诊治探讨. 中国小儿血液与肿瘤杂志, 2020, 25(4): 206-209. doi:10.3969/j.issn.1673-5323.2020.04.005.
|
| [24] |
胡晓萌, 熊磊群, 杜鹃. 耐药肺结核合并慢性粒细胞白血病及Gilbert综合征1例. 中华结核和呼吸杂志, 2023, 46(3): 281-284. doi:10.3760/cn112147-20221201-00942.
|
| [25] |
韩美玲, 金武, 杜鹃. 耐多药肺结核合并慢性粒细胞白血病1例. 中国临床案例成果数据库, 2023, 5(1):E00589. doi:10.3760/cma.j.cmcr.2023.e00589.
|
| [26] |
樊丽超, 焦伟伟, 吴浩宇, 等. 世界卫生组织《结核病整合指南模块5:儿童和青少年结核病管理》解读. 中国防痨杂志, 2023, 45(1): 6-12. doi:10.19982/j.issn.1000-6621.20220403.
|
)
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
